Article Contents ::
- 1 Details About Generic Salt :: Dobutami
- 2 Main Medicine Class:: Vasopressor
- 3 (doe-BYOOT-uh-meen) Dobutrex Class: Vasopressor
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Dobutami
Main Medicine Class:: Vasopressor
(doe-BYOOT-uh-meen)
Dobutrex
Class: Vasopressor
Drugs Class ::
Action Stimulates beta1-receptors in heart, causing more complete and forceful contractions (inotropy) without significantly increasing heart rate or BP.
Indications for Drugs ::
Indications Treatment of cardiac decompensation caused by organic heart disease or cardiac surgical procedures. Unlabeled use(s): Congenital heart disease in children undergoing diagnostic cardiac catheterization.
Drug Dose ::
Route/Dosage
ADULTS: IV infusion 2.5 to 10 mcg/kg/min; titrate to desired response; increase in heart rate > 10% may develop in rate > 20 mcg/kg/min; rates up to 40 mcg/kg/min are rarely used. Duration of therapy up to 72 hr without decrease in clinical effectiveness may be used.
Contraindication ::
Contraindications Idiopathic hypertrophic subaortic stenosis.
Drug Precautions ::
Precautions
Pregnancy: Safety not established. Lactation: Undetermined. Children: Safety and efficacy not established. Special risk patients: Use with extreme caution after myocardial ischemia. Avoid use in uncorrected hypovolemic states unless used as temporary emergency measure to maintain coronary and cerebral flow. Cardiovascular effects: May greatly increase BP and heart rate, especially with preexisting hypertension. Dose reduction may reverse effects. May precipitate or exacerbate ventricular ectopic activity. Hypokalemia: Mild hypokalemia may occur. Sulfite sensitivity: Use caution in sulfite-sensitive individuals; some preparations contain sodium bisulfite.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Increased systolic BP; increased heart rate; chest pain; increased number of premature ventricular beats. CNS: Headache; tingling sensations; paresthesia. GI: Nausea; vomiting. RESP: Dyspnea. OTHER: Phlebitis; local inflammation after infiltration; leg cramps.
Drug Mode of Action ::
Action Stimulates beta1-receptors in heart, causing more complete and forceful contractions (inotropy) without significantly increasing heart rate or BP.
Drug Interactions ::
Interactions
Beta-blockers: May antagonize beta receptor-stimulating activity of dobutamine. Furazolidone, methyldopa, rauwolfia alkaloids: Hypertension may result. Guanethidine: May increase pressor response. Halogenated hydrocarbon anesthetics: May increase risk of arrhythmias by sensitizing cardiac tissue to sympathomimetic agents. Tricyclic antidepressants: May potentiate effect of dobutamine; use combination with caution. Incompatibilities: Chemically incompatible with sodium bicarbonate or other alkaline solutions.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Monitor vital signs, ECG, cardiac output, pulmonary capillary wedge pressure, central venous pressure and urinary output carefully throughout infusion.
- Monitor potassium levels to detect possible hypokalemia.
- Monitor patency and placement of IV catheter to reduce risk of extravasation and phlebitis.
- If patient has diabetes, monitor blood glucose level. Report significant increase to physician.
|
Drug Storage/Management ::
Administration/Storage
- Administer by IV infusion only. Use electronic infusion device to monitor infusion rate.
- Reconstitution/dilution is done in two stages.
- First, more concentrated solution can be kept under refrigeration for 48 hr or at room temperature for 6 hr.
- Before administration, solution is further diluted to typical concentration of 0.25 to 1 mg/ml (250 to 1000 mcg/ml). Final concentration should not exceed 5 mg/ml. This solution should be used within 24 hr.
- Solution may have pink color, because of slight oxidation, but this effect does not indicate loss of potency.
- Do not freeze solution because crystallization may occur.
Drug Notes ::
Patient/Family Education
- Instruct patient to report these symptoms to physician: pain or discomfort at IV site, any anginal pain.